CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 255 enrolled
Drug / intervention
BPN14770 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03817684
NCT03817684Phase 2Completed
CompareCT.gov

A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease

Tetra Discovery Partners·interventional·Posted Jan 25, 2019·Updated Feb 18, 2025

In Brief

A Phase 2 clinical trial evaluating BPN14770 and Placebo for Alzheimer's Disease. Completed, enrolled 255 participants across 41 sites.

Detailed Summary

A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 25, 2019
Enrollment StartApr 30, 2019
Primary CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.4 years ago

Interventions

BPN14770drug

Drug BPN14770

Placebodrug

Placebo